Impact of Newly Diagnosed Cancer on Bleeding Events in Patients with Atrial Fibrillation Treated with Direct Oral Anticoagulants.
Francesco AngeliLuca BergamaschiMatteo ArmillottaAngelo SansonettiAndrea StefanizziLisa CantonFrancesca BodegaNicole SumaSara AmiconeDamiano FedeleDavide BertoliniAndrea ImpellizzeriFrancesco Pio TattiloDaniele CavalloLorenzo BartoliOrnella Di IuorioKhrystyna RyabenkoMarcello Casuso AlvarezVirginia MarinelliClaudio AstaMariachiara CiarlantiniGiuseppe PastoreAndrea RinaldiDaniela Paola PomataIlaria CaldareraCarmine PizziPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2024)
During follow-up, newly diagnosed primitive or metastatic cancer in patients with NVAF taking DOACs is a strong predictor of major bleeding regardless of baseline hemorrhagic risk assessment. In contrast, such an association is not observed with malignancy at baseline. Appropriate diagnosis and treatment could therefore reduce the risk of cancer-related bleeding.